Nautilus Biotechnology Inc
(NAUT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,965 | -57,924 | -44,515 | -30,452 | -15,763 |
| Depreciation Amortization | 502 | 2,526 | 2,155 | 1,488 | 832 |
| Accounts payable and accrued liabilities | 53 | -561 | -850 | -643 | -394 |
| Other Working Capital | -921 | -788 | -616 | -1,577 | 486 |
| Other Operating Activity | 2,807 | 10,941 | 8,397 | 5,320 | 2,504 |
| Operating Cash Flow | $-12,524 | $-45,806 | $-35,429 | $-25,864 | $-12,335 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -692 | -2,324 | -2,095 | -1,132 | -481 |
| Purchase Of Investment | -27,052 | -186,591 | -101,665 | -54,185 | -22,912 |
| Sale Of Investment | 14,249 | 163,175 | 142,075 | 105,575 | 38,575 |
| Investing Cash Flow | $-13,495 | $-25,740 | $38,315 | $50,258 | $15,182 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1 | 562 | 427 | 341 | 156 |
| Financing Cash Flow | $1 | $562 | $427 | $341 | $156 |
| Beginning Cash Position | 115,477 | 186,461 | 186,461 | 186,461 | 186,461 |
| End Cash Position | 89,459 | 115,477 | 189,774 | 211,196 | 189,464 |
| Net Cash Flow | $-26,018 | $-70,984 | $3,313 | $24,735 | $3,003 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,524 | -45,806 | -35,429 | -25,864 | -12,335 |
| Capital Expenditure | -692 | -2,324 | -2,095 | -1,132 | -481 |
| Free Cash Flow | -13,216 | -48,130 | -37,524 | -26,996 | -12,816 |